Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.60 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | KDM5A | P29375 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19763766 | 0.89 | KMT2A (0.49) | HCAR3HCAR2KMT2ANPSR1L3MBTL1 | |
| SCHEMBL19763764 | 0.89 | KMT2A (0.49) | HCAR3HCAR2KMT2ANPSR1L3MBTL1 | |
| SCHEMBL20515889 | 0.89 | KMT2A (0.49) | HCAR3HCAR2KMT2ANPSR1L3MBTL1 | |
| SCHEMBL28934823 | 0.88 | POLB (0.48) | HCAR3HCAR2KMT2ANPSR1L3MBTL1 | |
| SCHEMBL4178432 | 0.86 | KMT2A (0.49) | HCAR3HCAR2KMT2ANPSR1L3MBTL1 | |
| SCHEMBL24428117 | 0.85 | KMT2A (0.46) | HCAR3HCAR2KMT2ANPSR1L3MBTL1 | |
| SCHEMBL5599411 | 0.84 | KMT2A (0.48) | HCAR3HCAR2KMT2ANPSR1L3MBTL1 | |
| SCHEMBL29910437 | 0.82 | POLB (0.44) | HCAR3HCAR2KMT2ANPSR1L3MBTL1 | |
| SCHEMBL31088685 | 0.81 | HCAR3 (0.66) | HCAR3HCAR2KMT2AL3MBTL1POLB | |
| SCHEMBL20284378 | 0.80 | KMT2A (0.44) | HCAR3HCAR2KMT2ANPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3174886-B1 | 2-OXA-5-AZABICYCLO[2.2.1]HEPTAN-3-YL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-02-17 | — | — | EP | disclosed |
| US-10562897-B2 | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-18 | — | — | US | disclosed |
| CN-106661043-B | 2-oxa-5-azabicyclo [2.2.1] hept-3-yl derivatives | 豪夫迈·罗氏有限公司 | 2020-01-17 | — | — | CN | disclosed |
| US-10376494-B2 | Carboxamide derivative and its diastereomers in stable crystalline form | ORION CORPORATION (FI) | 2019-08-13 | — | — | US | disclosed |
| US-10246454-B2 | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-04-02 | — | — | US | disclosed |
| US-20180319797-A1 | NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-08 | — | — | US | disclosed |
| EP-3137459-B1 | MORPHOLIN-PYRIDINE DERIVATIVES HAVING AFFINITY TO THE TAAR1 RECEPTOR | HOFFMANN LA ROCHE (CH) | 2018-05-23 | — | — | EP | disclosed |
| US-9840501-B2 | Morpholin-pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9790230-B2 | 2-oxa-5-azabicyclo[2.2.1]heptan-3-yl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-3174886-A1 | 2-OXA-5-AZABICYCLO[2.2.1]HEPTAN-3-YL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-06-07 | — | — | EP | disclosed |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PFIZER INC. | 2004-11-04 | — | — | US | disclosed |
| EP-1444009-A1 | TREATMENT OF INSULIN RESISTANCE SYNDROME AND TYPE 2 DIABETES WITH PDE9 INHIBITORS | Pfizer Products Inc. (US) | 2004-08-11 | — | — | EP | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| EP-1440073-A1 | PDE9 INHIBITORS FOR TREATING CARDIOVASCULAR DISORDERS | Pfizer Limited (GB) | 2004-07-28 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| US-20040023989-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | FRYBURG DAVID A (US) | 2004-02-05 | — | — | US | disclosed |
| US-20030195205-A1 | PDE9 inhibitors for treating cardiovascular disorders | PFIZER INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003037432-A1 | TREATMENT OF INSULIN RESISTANCE SYNDROME AND TYPE 2 DIABETES WITH PDE9 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003037899-A1 | PDE9 INHIBITORS FOR TREATING CARDIOVASCULAR DISORDERS | PFIZER LIMITED (GB) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10376494-B2 | Carboxamide derivative and its diastereomers in stable crystalline form | AR, NR5A1, SHBG | HCAR3 101/4885HCAR2 92/4885KMT2A 1457/4885 |
| US-10246454-B2 | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators | BACE1, BACE2, PSEN1 | HCAR3 1984/4885HCAR2 1959/4885KMT2A 3158/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | HCAR3 3436/4885HCAR2 3979/4885KMT2A 1844/4885 |
| US-20030195205-A1 | PDE9 inhibitors for treating cardiovascular disorders | PDE9A, PDE2A, PDE3A | HCAR3 316/4885HCAR2 147/4885KMT2A 3060/4885 |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PDE9A, PDE2A, PDE12 | HCAR3 2587/4885HCAR2 1162/4885KMT2A 2217/4885 |
| US-20040023989-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | HCAR3 2113/4885HCAR2 1033/4885KMT2A 2168/4885 |
| US-10562897-B2 | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators | BACE1, BACE2, PSEN1 | HCAR3 1984/4885HCAR2 1959/4885KMT2A 3158/4885 |
| US-20180319797-A1 | NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | HCAR3 2125/4885HCAR2 2569/4885KMT2A 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.